TractionThe Blue Box has maintained capital efficiency throughout development, reaching clinical-ready stage with approximately €1.5 million in non-dilutive public funding and earlier angel rounds.FoundersJudit Giró, Lidia NavarroMarketBreast Cancer ScreeningLocationBarcelona, SpainCoinvestorsUnconventional Ventures, Fund F, Grow Ventures, Hans(wo)man Group, Krups Family Office, Spanish Association Against Cancer, Robert Masse, Torsten Kolind, Matt Cooper Company Description
The Blue Box has developed an artificial intelligence-powered urine-based screening test for breast cancer that analyzes volatile organic compounds, achieving 88% sensitivity in detecting breast cancer biomarkers, significantly improving upon traditional mammography methods.